A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

Gynecologic Oncology
H HomesleyR G Penley

Abstract

Topotecan is an established topoisomerase I inhibitor for the treatment of relapsed ovarian cancer. Myelotoxicity and suboptimal patient convenience associated with daily topotecan, however, have prompted investigators to explore alternate regimens, including a weekly regimen of topotecan. The objective of this study was to determine the maximum tolerated dose (MTD) of topotecan given as a weekly bolus in previously treated ovarian cancer patients. Second- and third-line ovarian cancer patients with measurable disease or elevated cancer antigen 125 received weekly bolus topotecan intravenously starting at 1.5 mg/m(2). Topotecan was escalated in dose increments of 0.5 mg/m(2) every 21 days as tolerability allowed. Dose-limiting toxicity was defined as grade 3/4 neutropenia or thrombocytopenia. Thirty-two of 35 patients were evaluable for safety and tolerability. No notable toxicity was observed with weekly topotecan doses < 4 mg/m(2). Additionally, there was an absence of dose-limiting myelotoxicity and thrombocytopenia with weekly topotecan. The MTD of weekly topotecan without the use of granulocyte colony-stimulating factor support was 4 mg/m(2), with grade 2 anemia, chronic fatigue, and grade 2 gastrointestinal toxicity limit...Continue Reading

Associated Clinical Trials

References

Aug 6, 1997·Journal of the National Cancer Institute·R SimonM C Christian
Sep 23, 1997·Gynecologic Oncology·E M SwisherT J Herzog
Aug 10, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M De CesareG Pratesi

❮ Previous
Next ❯

Citations

Dec 14, 2004·The New England Journal of Medicine·Stephen A Cannistra
Feb 1, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·K F TamH Y S Ngan
Mar 17, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·F VecchioneA A Lissoni
Sep 24, 2004·Gynecologic Oncology·Tiffany A TrainaJakob Dupont
Jan 1, 2006·Women's Health·Gamal H Eltabbakh, Scott Goodrich
Mar 21, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J Y Douillard, J Schiller
Feb 15, 2003·Gynecologic Oncology·John V BrownJohn Paul Micha
May 18, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A H Comander, S A Cannistra
Mar 13, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·J V BrownB Goldstein
Oct 14, 2005·Current Oncology Reports·Krishnansu S Tewari, Bradley J Monk
Sep 27, 2007·Acta Oncologica·Wan Teck LimRamaswamy Govindan
May 13, 2008·Expert Review of Anticancer Therapy·Stephanie L WethingtonThomas J Herzog
May 26, 2006·Expert Opinion on Pharmacotherapy·D PectasidesT Economopoulos
Oct 6, 2005·Cancer Investigation·Tarun Wasil, Stuart M Lichtman
Jun 4, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·David R SpigelF Anthony Greco
Nov 16, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F ZanaboniF Raspagliesi
Jun 15, 2011·Clinical Lung Cancer·David R SpigelJohn D Hainsworth
Jul 16, 2010·Clinical Lung Cancer·Noriyuki MasudaMasahiro Fukuoka
Oct 2, 2007·Gynecologic Oncology·Fadi AbushahinJulian C Schink
Apr 1, 2009·Seminars in Oncology·Lainie P Martin, Russell J Schilder
Dec 8, 2004·Gynecologic Oncology·Snehal M BhoolaRonald D Alvarez
Sep 26, 2006·Gynecologic Oncology·John C ElkasG Scott Rose
Jul 5, 2005·Gynecologic Oncology·David M O'MalleyThomas Rutherford
Apr 3, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Chirag ShahStephen Garziano
Nov 5, 2002·Best Practice & Research. Clinical Obstetrics & Gynaecology·Nelson Gustavo Neder Kalil, William Patrick McGuire
May 25, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry J LongUNKNOWN Gynecologic Oncology Group Study

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.